Immune markers and mental fatigue in Graves' disease
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This study looks at whether certain immune system markers are linked to mental fatigue (feeling tired or foggy in the mind) in people with newly diagnosed Graves' disease. If you join, you'll help researchers understand how your immune system might affect your energy and thinking.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Graves' disease recently (within the last few weeks).
- A blood test shows you have TRAb antibodies that stimulate your thyroid.
- Your thyroid hormone levels are higher than normal.
- You started taking thyroid-lowering medication within the last 3 weeks.
- You are not pregnant, and you do not have dementia, psychosis, or any other condition that would make it hard to follow the study or answer questions in Swedish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood “immune” markers to understand why some people with Graves’ disease develop mental fatigue (feeling slowed down in thinking). It may help doctors better recognize and explain mental fatigue in Graves’ disease.
This study tests a course designed to help with brain fatigue (mental tiredness) that can happen after Graves' disease. It is for people whose thyroid levels are stable but who still struggle with fatigue.
This trial studies how thyroid hormone levels affect your body's use of sugar and energy. It may help people newly diagnosed with Graves' disease or thyroid cancer understand their metabolism better.
This study compares different treatment plans to see how well they control Graves’ disease and whether it comes back. It may help by identifying which approach works best to prevent relapse.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
This study compares computer-guided dosing of methimazole (a common thyroid medication) to standard care for people with active Graves' disease. It tests whether digital support helps manage treatment better.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.